BioCentury
ARTICLE | Financial News

June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more

June 25, 2019 10:41 PM UTC

Tasly Biopharma looks to list in Hong Kong
Tasly Biopharmaceutical Co. Ltd. (Shanghai, China) proposed to list on the Hong Kong exchange. The company is a subsidiary of Tasly Pharmaceutical (Shanghai:600535), which holds 87.75% of the company’s equity. Other shareholders include Ally Bridge, Pudong Science and Technology, Southern Creation, BOCOM International Holdings and Grand Riches Investment, which together invested $84.5 million in the company last July. Tasly Biopharmaceutical markets thrombolytic drug pro-UK for ST-segment elevation myocardial infarction in China and has 13 other biologics in preclinical to Phase III testing for cancer, metabolic, gastrointestinal, cardiovascular and autoimmune diseases.

Vesalius closes fund at €120 million
Vesalius Biocapital Partners closed its third fund at €120 million ($136.7 million). The fund, which will invest in later-stage European life science companies, had its first close in 2017 (see “Larger and Later”)...